Oncology Nursing in Europe

Publication
Article
OncologyONCOLOGY Vol 11 No 11
Volume 11
Issue 11

Presenting the nursing perspective on cancer, Ms. Nora Jodrell, Macmillan Lecturer in Cancer Nursing and President Elect of

Presenting the nursing perspective on cancer, Ms. Nora Jodrell, Macmillan Lecturer in Cancer Nursing and President Elect of the European Oncology Nursing Society, explained that the priorities of cancer nursing throughout Europe are to improve the quality of care received by individuals and to reduce the morbidity and mortality associated with cancer.

“Nurses are responding to these challenges through a number of educational initiatives that are supported by the European Commission’s Europe Against Cancer Program and extensively used throughout Europe in the development of educational curriculum,” said Ms. Jodrell. “And nursing research is addressing the experience of living with cancer. I anticipate that, as the profile of cancer nursing is raised across Europe, patients will have readier access to the supportive services offered by the nursing profession, and this will enhance the quality of life for patients.”

Ms. Jodrell predicts that advances in cancer genetics and molecular biology will lead to a new era of cancer management. She further suggests that a more patient-focused health-care system will develop, which will lead to an increasingly specialized role for cancer nurses.

“As cancer care shifts from hospital to home, patients and their families will increasingly rely on skilled nurses to support them through treatment. This is already happening with chemotherapy regimens for children with cancer which are increasingly being managed in daycare centers or at home,” added Ms Jodrell. 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content